Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Prevalence and risk factors of tuberculosis disease in South African correctional facilities in 2015.

Jordan AM, Podewils LJ, Castro KG, Zishiri V, Charalambous S.

Int J Tuberc Lung Dis. 2019 Nov 1;23(11):1198-1204. doi: 10.5588/ijtld.18.0782.

PMID:
31718756
2.

Poly (ADP) Ribose Glycohydrolase Can Be Effectively Targeted in Pancreatic Cancer.

Jain A, Agostini LC, McCarthy GA, Chand SN, Ramirez A, Nevler A, Cozzitorto J, Schultz CW, Lowder CY, Smith KM, Waddell ID, Raitses-Gurevich M, Stossel C, Gorman YG, Atias D, Yeo CJ, Winter JM, Olive KP, Golan T, Pishvaian MJ, Ogilvie D, James DI, Jordan AM, Brody JR.

Cancer Res. 2019 Sep 1;79(17):4491-4502. doi: 10.1158/0008-5472.CAN-18-3645. Epub 2019 Jul 4.

PMID:
31273064
3.

DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.

Pillay N, Tighe A, Nelson L, Littler S, Coulson-Gilmer C, Bah N, Golder A, Bakker B, Spierings DCJ, James DI, Smith KM, Jordan AM, Morgan RD, Ogilvie DJ, Foijer F, Jackson DA, Taylor SS.

Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.

4.

Fluoromethylcyclopropylamine derivatives as potential in vivo toxicophores - A cautionary disclosure.

Acton B, Small HF, Smith KM, McGonagle A, Stowell AIJ, James DI, Hamilton NM, Hamilton N, Hitchin JR, Hutton CP, Waddell ID, Ogilvie DJ, Jordan AM.

Bioorg Med Chem Lett. 2019 Feb 15;29(4):560-562. doi: 10.1016/j.bmcl.2018.12.066. Epub 2019 Jan 2.

5.

Artificial Intelligence in Drug Design-The Storm Before the Calm?

Jordan AM.

ACS Med Chem Lett. 2018 Nov 2;9(12):1150-1152. doi: 10.1021/acsmedchemlett.8b00500. eCollection 2018 Dec 13.

6.

Cell-Active Small Molecule Inhibitors of the DNA-Damage Repair Enzyme Poly(ADP-ribose) Glycohydrolase (PARG): Discovery and Optimization of Orally Bioavailable Quinazolinedione Sulfonamides.

Waszkowycz B, Smith KM, McGonagle AE, Jordan AM, Acton B, Fairweather EE, Griffiths LA, Hamilton NM, Hamilton NS, Hitchin JR, Hutton CP, James DI, Jones CD, Jones S, Mould DP, Small HF, Stowell AIJ, Tucker JA, Waddell ID, Ogilvie DJ.

J Med Chem. 2018 Dec 13;61(23):10767-10792. doi: 10.1021/acs.jmedchem.8b01407. Epub 2018 Nov 19.

PMID:
30403352
7.

Synthesis and characterization of rhodium, iridium, and palladium complexes of a diarylamido-based PNSb pincer ligand.

Kosanovich AJ, Jordan AM, Bhuvanesh N, Ozerov OV.

Dalton Trans. 2018 Aug 21;47(33):11619-11624. doi: 10.1039/c8dt02207k.

PMID:
30091437
8.

Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.

Maiques-Diaz A, Spencer GJ, Lynch JT, Ciceri F, Williams EL, Amaral FMR, Wiseman DH, Harris WJ, Li Y, Sahoo S, Hitchin JR, Mould DP, Fairweather EE, Waszkowycz B, Jordan AM, Smith DL, Somervaille TCP.

Cell Rep. 2018 Mar 27;22(13):3641-3659. doi: 10.1016/j.celrep.2018.03.012.

9.

Development and evaluation of 4-(pyrrolidin-3-yl)benzonitrile derivatives as inhibitors of lysine specific demethylase 1.

Mould DP, Bremberg U, Jordan AM, Geitmann M, McGonagle AE, Somervaille TCP, Spencer GJ, Ogilvie DJ.

Bioorg Med Chem Lett. 2017 Oct 15;27(20):4755-4759. doi: 10.1016/j.bmcl.2017.08.052. Epub 2017 Aug 24.

PMID:
28927796
10.

Development of (4-Cyanophenyl)glycine Derivatives as Reversible Inhibitors of Lysine Specific Demethylase 1.

Mould DP, Alli C, Bremberg U, Cartic S, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Somervaille TCP, Spencer GJ, Turlais F, Ogilvie D.

J Med Chem. 2017 Oct 12;60(19):7984-7999. doi: 10.1021/acs.jmedchem.7b00462. Epub 2017 Sep 21.

PMID:
28892629
11.

Development of 5-hydroxypyrazole derivatives as reversible inhibitors of lysine specific demethylase 1.

Mould DP, Bremberg U, Jordan AM, Geitmann M, Maiques-Diaz A, McGonagle AE, Small HF, Somervaille TCP, Ogilvie D.

Bioorg Med Chem Lett. 2017 Jul 15;27(14):3190-3195. doi: 10.1016/j.bmcl.2017.05.018. Epub 2017 May 8.

PMID:
28545974
12.

Semibatch monomer addition as a general method to tune and enhance the mechanics of polymer networks via loop-defect control.

Gu Y, Kawamoto K, Zhong M, Chen M, Hore MJA, Jordan AM, Korley LTJ, Olsen BD, Johnson JA.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):4875-4880. doi: 10.1073/pnas.1620985114. Epub 2017 Apr 24.

13.

Living Additive Manufacturing: Transformation of Parent Gels into Diversely Functionalized Daughter Gels Made Possible by Visible Light Photoredox Catalysis.

Chen M, Gu Y, Singh A, Zhong M, Jordan AM, Biswas S, Korley LT, Balazs AC, Johnson JA.

ACS Cent Sci. 2017 Feb 22;3(2):124-134. doi: 10.1021/acscentsci.6b00335. Epub 2017 Jan 13.

14.

Communicating Our Science to Our Customers: The Vital Role of Passionate Public Advocacy.

Jordan AM, Grant RP.

ACS Med Chem Lett. 2016 Oct 20;7(12):1010-1011. eCollection 2016 Dec 8.

15.

First-in-Class Chemical Probes against Poly(ADP-ribose) Glycohydrolase (PARG) Inhibit DNA Repair with Differential Pharmacology to Olaparib.

James DI, Smith KM, Jordan AM, Fairweather EE, Griffiths LA, Hamilton NS, Hitchin JR, Hutton CP, Jones S, Kelly P, McGonagle AE, Small H, Stowell AI, Tucker J, Waddell ID, Waszkowycz B, Ogilvie DJ.

ACS Chem Biol. 2016 Nov 18;11(11):3179-3190. Epub 2016 Oct 12.

PMID:
27689388
16.

Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2.

Hornyak P, Askwith T, Walker S, Komulainen E, Paradowski M, Pennicott LE, Bartlett EJ, Brissett NC, Raoof A, Watson M, Jordan AM, Ogilvie DJ, Ward SE, Atack JR, Pearl LH, Caldecott KW, Oliver AW.

Biochem J. 2016 Jul 1;473(13):1869-79. doi: 10.1042/BCJ20160180. Epub 2016 Apr 20.

17.

Anilinoquinazoline inhibitors of the RET kinase domain-Elaboration of the 7-position.

Jordan AM, Begum H, Fairweather E, Fritzl S, Goldberg K, Hopkins GV, Hamilton NM, Lyons AJ, March HN, Newton R, Small HF, Vishwanath S, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

Bioorg Med Chem Lett. 2016 Jun 1;26(11):2724-9. doi: 10.1016/j.bmcl.2016.03.100. Epub 2016 Mar 30.

18.

The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity.

Newton R, Bowler KA, Burns EM, Chapman PJ, Fairweather EE, Fritzl SJR, Goldberg KM, Hamilton NM, Holt SV, Hopkins GV, Jones SD, Jordan AM, Lyons AJ, Nikki March H, McDonald NQ, Maguire LA, Mould DP, Purkiss AG, Small HF, Stowell AIJ, Thomson GJ, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

Eur J Med Chem. 2016 Apr 13;112:20-32. doi: 10.1016/j.ejmech.2016.01.039. Epub 2016 Jan 29.

19.

ERK5 is a critical mediator of inflammation-driven cancer.

Finegan KG, Perez-Madrigal D, Hitchin JR, Davies CC, Jordan AM, Tournier C.

Cancer Res. 2015 Feb 15;75(4):742-53. doi: 10.1158/0008-5472.CAN-13-3043. Epub 2015 Feb 3.

20.

Rethinking 'academic' drug discovery: the Manchester Institute perspective.

Jordan AM, Waddell ID, Ogilvie DJ.

Drug Discov Today. 2015 May;20(5):525-35. doi: 10.1016/j.drudis.2014.12.011. Epub 2014 Dec 24. Review.

PMID:
25542353
21.

Reversible inhibitors of LSD1 as therapeutic agents in acute myeloid leukemia: clinical significance and progress to date.

Mould DP, McGonagle AE, Wiseman DH, Williams EL, Jordan AM.

Med Res Rev. 2015 May;35(3):586-618. doi: 10.1002/med.21334. Epub 2014 Nov 24. Review.

PMID:
25418875
22.

Surface Modification of Melt Extruded Poly(ε-caprolactone) Nanofibers: Toward a New Scalable Biomaterial Scaffold.

Kim SE, Wang J, Jordan AM, Korley LT, Baer E, Pokorski JK.

ACS Macro Lett. 2014 Jun 17;3(6):585-589. Epub 2014 Jun 6.

23.

No lasting legacy: no change in reporting of women's sports in the British print media with the London 2012 Olympics and Paralympics.

Packer C, Geh DJ, Goulden OW, Jordan AM, Withers GK, Wagstaff AJ, Bellwood RA, Binmore CL, Webster CL.

J Public Health (Oxf). 2015 Mar;37(1):50-6. doi: 10.1093/pubmed/fdu018. Epub 2014 Mar 11.

24.

Structural evolution during mechanical deformation in high-barrier PVDF-TFE/PET multilayer films using in situ X-ray techniques.

Jordan AM, Lenart WR, Carr JM, Baer E, Korley LT.

ACS Appl Mater Interfaces. 2014 Mar 26;6(6):3987-94. doi: 10.1021/am4053893. Epub 2014 Mar 4.

PMID:
24593226
25.

Torin1-mediated TOR kinase inhibition reduces Wee1 levels and advances mitotic commitment in fission yeast and HeLa cells.

Atkin J, Halova L, Ferguson J, Hitchin JR, Lichawska-Cieslar A, Jordan AM, Pines J, Wellbrock C, Petersen J.

J Cell Sci. 2014 Mar 15;127(Pt 6):1346-56. doi: 10.1242/jcs.146373. Epub 2014 Jan 14.

26.

Acute and chronic effects of diphenhydramine and sertraline mixtures in Ceriodaphnia dubia.

Goolsby EW, Mason CM, Wojcik JT, Jordan AM, Black MC.

Environ Toxicol Chem. 2013 Dec;32(12):2866-9. doi: 10.1002/etc.2378. Epub 2013 Oct 18.

PMID:
23996615
27.

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II.

Raoof A, Depledge P, Hamilton NM, Hamilton NS, Hitchin JR, Hopkins GV, Jordan AM, Maguire LA, McGonagle AE, Mould DP, Rushbrooke M, Small HF, Smith KM, Thomson GJ, Turlais F, Waddell ID, Waszkowycz B, Watson AJ, Ogilvie DJ.

J Med Chem. 2013 Aug 22;56(16):6352-70. doi: 10.1021/jm400568p. Epub 2013 Jul 31.

PMID:
23859074
28.

Diversity of Mycobacterium tuberculosis isolates from new pulmonary tuberculosis cases in Addis Ababa, Ethiopia.

Mihret A, Bekele Y, Loxton AG, Jordan AM, Yamuah L, Aseffa A, Howe R, Walzl G.

Tuberc Res Treat. 2012;2012:892079. doi: 10.1155/2012/892079. Epub 2012 Nov 22.

29.

Toward anisotropic materials via forced assembly coextrusion.

Burt TM, Jordan AM, Korley LT.

ACS Appl Mater Interfaces. 2012 Oct 24;4(10):5155-61. doi: 10.1021/am301072s. Epub 2012 Sep 19.

PMID:
22991945
30.

Novel steroid inhibitors of glucose 6-phosphate dehydrogenase.

Hamilton NM, Dawson M, Fairweather EE, Hamilton NS, Hitchin JR, James DI, Jones SD, Jordan AM, Lyons AJ, Small HF, Thomson GJ, Waddell ID, Ogilvie DJ.

J Med Chem. 2012 May 10;55(9):4431-45. doi: 10.1021/jm300317k. Epub 2012 Apr 27.

PMID:
22506561
31.

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.

Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, Miller CJ, Ogilvie DJ, Somervaille TC.

Cancer Cell. 2012 Apr 17;21(4):473-87. doi: 10.1016/j.ccr.2012.03.014. Epub 2012 Mar 29. Erratum in: Cancer Cell. 2012 Jun 12;21(6):856.

32.

The medicinal chemist's toolbox: an analysis of reactions used in the pursuit of drug candidates.

Roughley SD, Jordan AM.

J Med Chem. 2011 May 26;54(10):3451-79. doi: 10.1021/jm200187y. Epub 2011 May 2. No abstract available.

PMID:
21504168
33.

Antifungal metabolites (monorden, monocillins I, II, III) from Colletotrichum graminicola, a systemic vascular pathogen of maize.

Wicklow DT, Jordan AM, Gloer JB.

Mycol Res. 2009 Dec;113(Pt 12):1433-42. doi: 10.1016/j.mycres.2009.10.001. Epub 2009 Oct 13.

PMID:
19825415
34.

Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor.

Bedford ST, Benwell KR, Brooks T, Chen I, Comer M, Dugdale S, Haymes T, Jordan AM, Kennett GA, Knight AR, Klenke B, LeStrat L, Merrett A, Misra A, Lightowler S, Padfield A, Poullennec K, Reece M, Simmonite H, Wong M, Yule IA.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5945-9. doi: 10.1016/j.bmcl.2009.08.040. Epub 2009 Aug 14.

PMID:
19733067
35.

Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.

Gillespie RJ, Bamford SJ, Clay A, Gaur S, Haymes T, Jackson PS, Jordan AM, Klenke B, Leonardi S, Liu J, Mansell HL, Ng S, Saadi M, Simmonite H, Stratton GC, Todd RS, Williamson DS, Yule IA.

Bioorg Med Chem. 2009 Sep 15;17(18):6590-605. doi: 10.1016/j.bmc.2009.07.078. Epub 2009 Aug 5.

PMID:
19695884
36.

Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone.

Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, Davis B, Drysdale MJ, Dymock B, Eccles SA, Garcia-Echeverria C, Fromont C, Hayes A, Hubbard RE, Jordan AM, Jensen MR, Massey A, Merrett A, Padfield A, Parsons R, Radimerski T, Raynaud FI, Robertson A, Roughley SD, Schoepfer J, Simmonite H, Sharp SY, Surgenor A, Valenti M, Walls S, Webb P, Wood M, Workman P, Wright L.

J Med Chem. 2009 Aug 13;52(15):4794-809. doi: 10.1021/jm900357y.

PMID:
19610616
37.

Drug discovery chemistry: a primer for the non-specialist.

Jordan AM, Roughley SD.

Drug Discov Today. 2009 Aug;14(15-16):731-44. doi: 10.1016/j.drudis.2009.04.005. Epub 2009 May 4. Review.

PMID:
19416759
38.

Antagonists of the human A(2A) receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides.

Gillespie RJ, Bamford SJ, Gaur S, Jordan AM, Lerpiniere J, Mansell HL, Stratton GC.

Bioorg Med Chem Lett. 2009 May 15;19(10):2664-7. doi: 10.1016/j.bmcl.2009.03.142. Epub 2009 Apr 1.

PMID:
19362836
39.

Antagonists of the human A(2A) adenosine receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines.

Gillespie RJ, Bamford SJ, Botting R, Comer M, Denny S, Gaur S, Griffin M, Jordan AM, Knight AR, Lerpiniere J, Leonardi S, Lightowler S, McAteer S, Merrett A, Misra A, Padfield A, Reece M, Saadi M, Selwood DL, Stratton GC, Surry D, Todd R, Tong X, Ruston V, Upton R, Weiss SM.

J Med Chem. 2009 Jan 8;52(1):33-47. doi: 10.1021/jm800961g.

PMID:
19072055
40.

Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines.

Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Jordan AM, Knight AR, Lerpiniere J, Misra A, Pratt RM, Roffey J, Stratton GC, Upton R, Weiss SM, Williamson DS.

Bioorg Med Chem Lett. 2008 May 1;18(9):2924-9. doi: 10.1016/j.bmcl.2008.03.072. Epub 2008 Mar 30.

PMID:
18411049
41.

Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.

Gillespie RJ, Cliffe IA, Dawson CE, Dourish CT, Gaur S, Giles PR, Jordan AM, Knight AR, Lawrence A, Lerpiniere J, Misra A, Pratt RM, Todd RS, Upton R, Weiss SM, Williamson DS.

Bioorg Med Chem Lett. 2008 May 1;18(9):2920-3. doi: 10.1016/j.bmcl.2008.03.076. Epub 2008 Mar 30.

PMID:
18407496
42.

Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.

Gillespie RJ, Adams DR, Bebbington D, Benwell K, Cliffe IA, Dawson CE, Dourish CT, Fletcher A, Gaur S, Giles PR, Jordan AM, Knight AR, Knutsen LJ, Lawrence A, Lerpiniere J, Misra A, Porter RH, Pratt RM, Shepherd R, Upton R, Ward SE, Weiss SM, Williamson DS.

Bioorg Med Chem Lett. 2008 May 1;18(9):2916-9. doi: 10.1016/j.bmcl.2008.03.075. Epub 2008 Mar 30.

PMID:
18406614
43.

4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.

Brough PA, Aherne W, Barril X, Borgognoni J, Boxall K, Cansfield JE, Cheung KM, Collins I, Davies NG, Drysdale MJ, Dymock B, Eccles SA, Finch H, Fink A, Hayes A, Howes R, Hubbard RE, James K, Jordan AM, Lockie A, Martins V, Massey A, Matthews TP, McDonald E, Northfield CJ, Pearl LH, Prodromou C, Ray S, Raynaud FI, Roughley SD, Sharp SY, Surgenor A, Walmsley DL, Webb P, Wood M, Workman P, Wright L.

J Med Chem. 2008 Jan 24;51(2):196-218. Epub 2007 Nov 20.

PMID:
18020435
44.

Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches.

Richardson CM, Gillespie RJ, Williamson DS, Jordan AM, Fink A, Knight AR, Sellwood DM, Misra A.

Bioorg Med Chem Lett. 2006 Dec 1;16(23):5993-7. Epub 2006 Sep 12.

PMID:
16971117
45.

4-Amino derivatives of the Hsp90 inhibitor CCT018159.

Barril X, Beswick MC, Collier A, Drysdale MJ, Dymock BW, Fink A, Grant K, Howes R, Jordan AM, Massey A, Surgenor A, Wayne J, Workman P, Wright L.

Bioorg Med Chem Lett. 2006 May 1;16(9):2543-8. Epub 2006 Feb 9.

PMID:
16480864
46.

Synthesis and analysis of urea and carbamate prodrugs as candidates for melanocyte-directed enzyme prodrug therapy (MDEPT).

Jordan AM, Khan TH, Malkin H, Osborn HM.

Bioorg Med Chem. 2002 Aug;10(8):2625-33.

PMID:
12057651
47.

Melanocyte-Directed enzyme prodrug therapy (MDEPT): development of second generation prodrugs for targeted treatment of malignant melanoma.

Jordan AM, Khan TH, Malkin H, Osborn HM, Photiou A, Riley PA.

Bioorg Med Chem. 2001 Jun;9(6):1549-58.

PMID:
11408174
48.

Melanocyte-directed enzyme prodrug therapy (MDEPT): development of a targeted treatment for malignant melanoma.

Jordan AM, Khan TH, Osborn HM, Photiou A, Riley PA.

Bioorg Med Chem. 1999 Sep;7(9):1775-80.

PMID:
10530924
49.

2'-Deacetoxyaustrospicatine from the stem bark of Taxus baccata.

Breeden SW, Jordan AM, Lawrence NJ, McGown AT.

Planta Med. 1996 Feb;62(1):94-5. No abstract available.

PMID:
17252428
50.

Control of tsetse flies (Diptera: Glossinidae) with the aid of attractants.

Jordan AM.

J Am Mosq Control Assoc. 1995 Jun;11(2 Pt 2):249-55. Review.

PMID:
7595456

Supplemental Content

Loading ...
Support Center